Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision
The exclusive power that Regulation No 726/2004 confers on the EMA in fact relates only to the evaluations carried out so that the Commission can issue the MA for a medicinal product. [See, in particular, Articles 5 to 9 of Regulation No …
25 Jul 2018 · 62017CC0029
Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision
In the same opinion, the CHMP, pursuant to Article 7 of Regulation No 726/2004, recommended, by consensus, that a marketing authorisation be granted for Tecfidera. Moreover, on the basis of an examination of the scientific evidence and in …
5 May 2021 · 62018TJ0611
Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision
24 Apr 2009 · 62009TO0052
BSG, Urteil vom 29. Juni 2023 - B 1 KR 35/21 RDecision
29 Jun 2023 · KSRE123960131
Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision
Article 4 of the regulation lays down that applications for MA are to be submitted to the European Medicines Agency (EMA). The requirements for the submission and examination of those applications are set out in Articles 5 to 15 of the …
21 Nov 2018 · 62017CJ0029
Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision
On 23 July 2021, the CHMP, pursuant to Article 7 of Regulation No 726/2004, issued an opinion recommending, by consensus, that the Commission grant an MA for Nexviadyme and finding that avalglucosidase alfa was not an NAS (‘the CHMP …
24 Sep 2025 · 62022TJ0483
Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision
Articles 4 to 10 set out the procedure relating to applications for the authorisation of a medicinal product. Applications are to be submitted to the European Medicines Agency established under the Regulation, [See Articles 1 and 4(1).] …
31 Jan 2013 · 62011CC0535
Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision
Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …
3 Jul 2025 · 62024CO0139
Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision
Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …
3 Jul 2025 · 62024CO0148